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Importance: Currently there is no risk factor scale that identiﬁes older persons at risk of frailty.
Objectives: In this study, we identiﬁed signiﬁcant multisystem risk factors of frailty, developed a simple
frailty risk index, and evaluated it for use in primary care on an external validation cohort of community-
living older persons.
Design, Setting, and Participants: We used cross-sectional data of 1685 older adults aged 55 and older in
the Singapore Longitudinal Ageing Studies (SLAS) to identify 13 salient risk factors among 40 known and
putative risk factors of the frailty phenotype (weakness, slowness, low physical activity, weight loss, and
exhaustion). In a validation cohort (n ¼ 2478) followed for 2 years, we evaluated the validity of Frailty
Risk Index (FRI).
Main Outcomes and Measures: Frailty at baseline and functional dependency, hospitalization, and SF12
physical component summary (PCS) scores at 2-year follow-up were measured among people in the
validation cohort.
Results: The components (weighted scores) of the FRI are age older than 75 (2), no education (1), heart
failure (1), respiratory disorders (2), stroke (2), depressive symptoms (3), hearing impairment (3), visual
impairment (1), FEV1/FVC lower than 0.7 (1), eGFR lower than 60 mL/min/1.73m2 (1), nutritional risk
score of 3 or higher (2), anemia (1), and white cell counts ( 109/L) of 6.5 or more (1). In the validation
cohort, the FRI (0 to 12) was signiﬁcantly associated with prefrailty (OR, 1.20 per unit; 95% CI 1.19e1.27)
and frailty (OR 1.80 per unit; 95% CI 1.65e1.95). The FRI predicted subsequent IADL-ADL dependency
(OR1.19; 95% CI 1.11e1.27), hospitalization (OR .14; 95% CI 1.05e1.24), lowest quintile of SF12-PCS (OR
1.17; 95% CI 1.11e1.25), and combined adverse health outcomes (OR 1.16; 95% CI 1.09e1.22).
Conclusions and Relevance: The FRI is a validated instrument for assessing frailty risk in community-living
older persons. FRI may be a useful rapid assessment tool to identify vital body system deﬁcits underlying
the frailty syndrome.
 2014 AMDA e The Society for Post-Acute and Long-Term Care Medicine. This is an open access article
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and Long-Term Care Medicine. Thphysical frailty is potentially reversible. It is hence useful to objectively
detect frailty among frail elderly persons, as frailty indices serve a
useful purpose for risk stratiﬁcation, predicting need for institutional
care and planning of services needed.1
The Cardiovascular Health Study (CHS) frailty scale, consisting of a
combination of syndrome components (weight loss, exhaustion,
weakness, slowness, and reduced physical activity),2 is the most
widely used measure of frailty in research, but is cumbersome for
routine use in clinical settings.3 It deﬁnes frailty distinctly as a clinical
syndrome, and does not include risk factors. So far, no scale has been
developed to identify older persons at risk of frailty based on their
proﬁle of important risk factors. Other frailty scales, based on theis is an open access article under the CC BY-NC-ND license (http://creativecommons.
T.P. Ng et al. / JAMDA 15 (2014) 635e642636cumulative deﬁcit model or the multidimensional model, such as the
Frailty Index,4 Frailty Index Comprehensive Geriatric Assessment
(FI-CGA),5 the Multidimensional Prognostic Index (MPI) Index,6 the
FRAIL,7 and Gérontopôle Frailty Scale (GFS),8 include psychosocial,
medical risk factors, and ADL disability, but conﬂate risk factors with
adverse outcomes.
As frailty is a biologic syndrome due to multisystem declines in
physiological reserves, a large number of direct, indirect, and inter-
acting risk factors are involved in its causation.9 They include low
socioeconomic status, living alone, comorbidity, speciﬁc chronic dis-
eases, heart failure, anemia, diabetes, depression, cognitive impair-
ment, poor nutrition such as micronutrient deﬁciency, obesity, low
cholesterol, and immune markers of chronic inﬂammation such as
C-reactive protein (CRP) and interleukin-6 (IL-6).10e26 Few studies
have simultaneously investigated diverse and overlapping risk factors
together in the same participants to identify a minimal subset of
unique multisystem clinical indicators of frailty risk. In this study, we
developed a frailty risk prediction tool based on simple and routine
clinical measurements and externally validated it for use in primary
care using data from 2 cohorts of community-living older persons.
Method
Population Samples
The development and validation studies were conducted in 2
separate cohorts in the Singapore Longitudinal Ageing Studies. The
ﬁrst-wave cohort (SLAS-1, n ¼ 2805) recruited residents in the
southeast region of Singapore between 2003 and 2004, and followed
them up at 2 years and 4 years. A second-wave cohort (SLAS-2) used
identical methodologies and completed baseline survey for residents
in the southwest and south central regions of Singapore from 2010 to
2013 (n ¼ 2010 as of April 30, 2013). Previous publications have
detailed the SLAS study design, population sampling, and measure-
ments.27 The research was approved by the National University of
Singapore Institutional Review Board, and informed consent was
obtained from all participants (response rate 78%). At baseline, all
participants underwent 5 to 6 detailed interview sessions in their
homes, and on-site clinical assessments, performance-based testing,
and venesection by trained research personnel for an extensive range
of demographic, medical, biological, psychosocial, behavioral, and
neurocognitive variables.
The development study was conducted in the SLAS-2 sample, and
investigated 40 known and putative risk factors of phenotypic frailty,
excluding correlates such as difﬁculties in activities of daily living
(ADLs) and history of hospitalization, which are congruent outcomes
of frailty. We identiﬁed 14 independent multisystem risk factors
among them and derived a Frailty Risk Index (FRI). The FRI was
externally validated in the SLAS-1 cohort on its ability to predict the
prevalence of frailty at baseline and subsequent likelihood of func-
tional dependency, hospitalization, and impaired quality of life at
2-year follow-up.
The development study was based on baseline data of 1685 par-
ticipants, after excluding participants for whom data were not
available at the time for white cell counts (n ¼ 328) and/or
lymphocyte counts (n ¼ 271). The validation study was conducted on
2478 participants in the SLAS-1 with complete baseline data, and on
1585 participants who had complete follow-up data on instrumental
ADL (IADL)-ADL dependency, hospitalization, and Short Form 12
Physical Component Summary (SF12-PCS) measure of quality of life.
Measurements
In the development cohort, the physical frailty phenotype was
deﬁned using 5 criteria proposed and validated in the CardiovascularHealth Study (CHS)2: unintentional shrinking, slowness, weakness,
exhaustion, and low activity. The measurements used in this study to
deﬁne the frailty construct were similar but not identical to those
used in the original CHS study. A participant without any of the 5
components was deﬁned as nonfrail, 1 to 2 components as prefrail,
and 3 and more components as frail.
1. Unintentional shrinking: body mass index (BMI) of less than
18.5 kg/m2 and/or unintentional weight loss of 10 pounds
(4.5 kg) or more in the past 6 months.
2. Slowness was assessed using the 6-meter fast gait speed test,
using the average of 2 measurements, and the lowest quintile
values stratiﬁed for gender and height to classify participants
as slow.
3. Weakness: leg muscle strength was determined using domi-
nant knee extension, using the average value from 3 trials in
kilograms, standardized on gender and BMI strata. Participants
with knee extension strengths in the lowest quintiles were
classiﬁed as weak.
4. Exhaustion was measured with 3 questions on vitality domain
in the Medical Outcomes Study SF-1228: “Did you feel worn
out?” “Did you feel tired?” “Did you have a lot of energy?” with
total summed scores ranging from 3 to 15, and a higher score
indicating more energy. A score of less than 10 was used to
denote exhaustion.
5. Low activity: physical activities were assessed based on self-
reported time (in hours) spent doing light (eg, ofﬁce work,
driving a car, strolling, standing with little motion, personal
care), moderate, and vigorous activities (eg, gardening, brisk
walking, dancing, jogging, swimming, strenuous sports) on
weekdays and the weekend. The total amount of time spent on
performing moderate and vigorous activities per week and
activity time below the gender-speciﬁc lowest quintile was
used to denote frailty on this criterion.
In the validation cohort, the CHS criteria for phenotypic frailty
were modiﬁed based on the available data. Weakness was deﬁned by
the lowest quintile of performance on rising from chair test; slowness
was deﬁned by Performance-Oriented Mobility Assessment gait
performance score of 8 or lower; exhaustion was deﬁned by their
response (“not at all”) to “Did you have a lot of energy?”; low activity
was deﬁned by “none” self-report of participation in any physical
activity (walking or recreational or sports activity).
Another frailty scale, the FRAIL scale,7 is a simple rapid screening
test that has been developed and validated to allow physicians to
identify persons with the physical frailty syndrome for more
in-depth assessment. Accordingly we used data of the SLAS-1 par-
ticipants to score their responses (0 or 1) to Fatigue: energy (none
of the time); Resistance: climb stairs (limited a lot), Aerobic: activity
or work (limited a lot); Illnesses: 5 or more illnesses; Loss of
weight: unintended loss of 10 lb/4 kg in past 6 months, and clas-
siﬁed them as follows: frail, 3 or more; prefrail: 1 or 2. The FRAIL
scale was used in addition to the CHS Frailty scale as comparators in
evaluating the ability of the FRI scale to predict adverse health
outcomes.Candidate Variables
The candidate variables selected as potential predictors of the FRI
are well established or putative risk factors for physical frailty, and
were not congruent characteristics of frailty. Difﬁculties in perform-
ing IADL-ADL activities, history of hospitalization, falls, and symp-
toms congruent with physical frailty (such as climbing stairs, physical
work limitations, breathlessness) were excluded. Available bio-
markers of nutrition and inﬂammation, such as CRP, IL-6, folate, B12,
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routinely used in primary care settings, but biomarkers such as low
hemoglobin, white cell counts (WCCs), and lymphocyte counts were
used instead. Low hemoglobin is reportedly associated with frailty
and with elevated levels of circulating IL-6 levels in frail older adults.
WCC is a recognized cellular marker of systemic inﬂammation and
reportedly associated with frailty.15,20
Sociodemographic data included age, gender, ethnicity, education,
housing type (an indicator of socioeconomic status), marital status,
and living arrangement. Life style variables included self-reports of
current smoking and daily alcohol drinking. The self-report of a
medical disorder diagnosed and treated by a physician(s) was
recorded for 22 named diagnoses and other disorders. The presence
of hypertension, dyslipidemia, diabetes, and cardiac diseases was
supported by examination of medications used, physical examination
or blood tests, electrocardiogram, fasting blood glucose, or history of
coronary reperfusion procedures. The number of comorbidities was
estimated from the total count of medical disorders in the past 1 year.
Medications (prescription and over-the-counter) used by the partici-
pant in the past year were ascertained from self- or proxy-reports and
physical inspection of labels on pill bottles, boxes, and packets.
Polypharmacy was deﬁned as the use of 6 or more medications.
Depressive symptoms was measured by the Geriatric Depression Scale
(GDS), which has been validated for use in local Chinese, Malay, and
Indian participants.29,30 Scores range from 0 to 15, with a higher score
indicating more symptoms of depression, and a score of 5 or higher
denoting a clinically signiﬁcant level of depressive symptoms.
Cognitive function was evaluated by using translated and modiﬁed
versions of the Mini-mental State Examination (MMSE) that have
been validated for local use in Singaporean older adults.31 A score of
23 or less denoted cognitive impairment. Orthostatic hypotension was
determined by a systolic blood pressure (BP) drop of at least 20 mm
Hg (irrespective of the diastolic change), a diastolic BP drop of at least
10 mm Hg (irrespective of the systolic change), or a drop in either
(consensus OH) 3 minutes after standing up from a supine position.32
BMI in kg/m2 was analyzed as a binary variable (obesity versus no
obesity) using 30 kg/m2 as a cut point. Nutrition risk score was as-
sessed by a 10-item questionnaire recommended in the Nutrition
Screening Initiative (DETERMINE Your Nutritional Health).33,34 The
summed weighted scores range from 0 to 21, with a higher score
indicating poor nutritional status; a score of 3 or higher was used to
categorize a participant having high-risk nutritional status. Blood tests
include hemoglobin (g/dL), albumin (g/dL), lymphocytes (109/L),
WCCs (109/L), and total cholesterol (mmol/L). Fasting venous blood
was collected from each respondent after an overnight fast of 10
hours. Anemia was deﬁned using World Health Organization criteria:
hemoglobin lower than 12 g/L in women and lower than 13 g/L in
men. Low albumin was deﬁned as values lower than 40 g/L. High
cholesterol was deﬁned as values of 6.5 mmol/L or higher. Low WCCs
and lymphocyte counts were deﬁned by values in the corresponding
lowest tertiles. Pulmonary function was assessed by the ratio of
the forced expiratory volume in 1 second (FEV1) to the forced
vital capacity (FVC). Values of FEV1/FVC below 0.7 indicate chronic
airﬂow obstruction. Visual impairment was deﬁned as having cor-
rected binocular vision worse than 20/40, as used in other studies.35
Hearing impairment was assessed using self-report and the standard
whisper test.
Functional dependencywas assessed by self-reported difﬁculty and
requiring help on 1 or more IADL or basic ADL activities, previously
validated for use in the local population.36,37 Hospitalization was
determined by the participants’ self-reports of new hospitalizations
for any chronic medical conditions over the previous year. Quality of
life was measured using the Medical Outcomes Study SF12-PCS of
quality of life.28Data Analysis
All social-demographic, health, biochemical, and other character-
istics of the participants were dichotomized and described using
proportions. Bivariate associations of potential risk indicator variables
with frailty deﬁned by the CHS Frailty scale were analyzed based on
the Cochran-Mantel-Haenszel test. ADL disability, IADL disability,
falls, and hospitalization were not included as candidate risk pre-
dictor variables in the selection models. Stepwise logistic regression
(P < .05 for entry and P < .05 for retention in the model) was per-
formed to select signiﬁcant independent predictors of frailty. All
variables were entered as candidate predictor variables in the initial
regression model. The strengths of associations were estimated by
odds ratio (OR) and 95% conﬁdence interval (CI).
A summary risk score for frailty was derived from the
b coefﬁcients associated with the signiﬁcant predictor variables in the
ﬁnal selection model for frailty. We assigned a risk score for each
variable based on its coefﬁcient value, standardized with the lowest
value, which was assigned a value of 1, and rounded to the nearest
integer. The summary risk score for an individual was obtained by
summing the weighted scores of each of the risk factors.
Validation of the FRI on the external validation sample was per-
formed by analyzing the association of the FRI score as a continuous
variable with the observed proportions of prefrailty and frailty in
multinomial logistic regression models, and estimating the OR (95%
CI) of prefrailty and frailty associated with each unit of FRI score in
the baseline sample, together with receiver operating characteristics
(ROC) analyses. In the prospective follow-up data, longitudinal asso-
ciations of the FRI with adverse health outcomes (IADL-ADL disability,
hospitalization, lowest quintile of SF12-PCS) at the 2-year follow-up
were analyzed. The ability of the FRI to predict adverse health out-
comes was compared with the CHS Frailty scale and the FRAIL scale.
The relationships were analyzed on the whole sample (n ¼ 1585) and
on a sample of participants who were free of adverse health outcome
at baseline.
A 2-sided P value of less than .05 was considered as statistically
signiﬁcant. All analyses were performed by SAS (SAS Institute, Inc,
Cary, NC).
Results
In the development cohort (mean age, 66.7; SD, 7.76), 5% (n ¼ 90)
were frail and 42% (n ¼ 712) were prefrail. All but a few of the
candidate predictor variables were signiﬁcantly associated with
prefrailty-frailty (Table 1). All variables (except ADL disability, IADL
disability, hospitalization, and falls) were entered in a stepwise
backward selection prediction model of frailty (Table 2). A total of 13
signiﬁcant variables were derived in the ﬁnal selection model. They
were older age, having no education, heart failure, obstructive res-
piratory disorders (asthma and/or chronic obstructive pulmonary
disease [COPD]), stroke, depressive symptoms, hearing impairment,
visual impairment, chronic airﬂow obstruction (FEV1/FVC<0.70),
chronic kidney failure (estimated glomerular ﬁltration rate [eGFR]
<60 mL/min/1.73 m2), low hemoglobin, high nutritional risk, and
increased WCCs. Table 2 shows the b coefﬁcients and ORs for
prefrailty-frailty derived from this model and the risk scores assigned
to each risk factor.
Risk scores assigned to each of these risk factors were summated,
and in the validation cohort, the summary risk score (FRI) was related
to the prevalence of prefrailty and frailty (Table 3). Increasing sum-
med scores of FRI were clearly related to increasing prevalence of
prefrailty and frailty (Figure 1). In multinomial regression models
analyzing FRI as a continuous variable, the risk of frailty increased by
an estimated 80% per unit of FRI score, and 23% per unit of FRI score
Table 1
Bivariate Association of Measured Variables With Frailty in Development Cohort
(n ¼ 1685)
Factor Robust
n ¼ 883
Prefrail
n ¼ 712
Frail
n ¼ 90
P Value
Age 75þ 70 (7.9) 144 (20.2) 33 (36.7) <.001
Female 566 (64.1) 457 (64.2) 61 (67.8) .66
No formal education 133 (15.1) 186 (26.1) 31 (34.4) <.001
Low-end (1e2 room)
public housing
147 (16.7) 182 (25.6) 37 (41.1) <.001
Non-Chinese ethnicity 79 (9.0) 90 (12.6) 13 (14.4) .010
Single, divorced, widowed 256 (29.0) 280 (39.3) 47 (52.2) <.001
Living alone 114 (12.9) 133 (18.7) 24 (26.7) <.001
Current smoking 173 (19.7) 181 (25.5) 24 (27.3) .004
Daily alcohol drinking 30 (3.4) 17 (2.4) 1 (1.1) .114
No. of chronic medical
problems (>5)
157 (17.8) 195 (27.4) 47 (52.2) <.001
Cardiovascular disease 50 (5.7) 75 (10.5) 14 (15.6) <.001
Hypertension 513 (58.1) 454 (63.8) 72 (80.0) <.001
Diabetes 151 (17.1) 170 (23.9) 28 (31.1) <.001
Stroke 14 (1.6) 29 (4.1) 11 (12.2) <.001
Coronary heart disease 28 (3.2) 32 (4.5) 7 (7.8) .028
Atrial ﬁbrillation 19 (2.2) 31 (4.4) 4 (4.4) .016
Heart failure 6 (0.7) 16 (2.3) 3 (3.3) .003
Cataracts/glaucoma 232 (26.3) 234 (32.9) 46 (51.1) <.001
Asthma/COPD 28 (3.2) 44 (6.2) 10 (11.1) <.001
Thyroid disease 41 (4.6) 41 (5.8) 1 (1.1) .86
Arthritis 119 (13.5) 112 (15.7) 18 (20.0) .063
Osteoporosis 41 (4.6) 48 (6.7) 11 (12.2) .003
Gastrointestinal problems 52 (5.9) 56 (7.9) 14 (15.6) .002
Cancer 23 (2.6) 16 (2.3) 6 (6.7) .29
Chronic kidney disease 40 (4.5) 77 (10.8) 17 (18.9) <.001
Poor self-rated health 3 (0.3) 9 (1.3) 6 (6.7) <.001
Depressive symptoms (GDS 5) 7 (0.8) 20 (2.8) 9 (10.0) <.001
Cognitive impairment
(MMSE score 23)
36 (4.1) 60 (8.4) 20 (22.2) <.001
Polypharmacy (>5 drugs) 88 (10.0) 143 (20.1) 26 (28.9) <.001
Orthostatic hypotension 9 (1.0) 18 (2.5) 1 (1.1) .098
Obesity (BMI 30) 45 (5.1) 53 (7.4) 12 (13.3) .002
High nutritional risk (score 3) 193 (21.9) 267 (37.5) 48 (53.3) <.001
Low albumin (<40 g/L) 78 (8.8) 94 (13.2) 17 (18.9) <.001
Anemia 308 (34.9) 292 (41.0) 43 (47.8) .002
Low total cholesterol
(0w5.19 mmol/L)
411 (47.0) 369 (52.3) 49 (55.1) .022
Low lymphocyte counts
(0w2.14 x 109/L)
586 (67.8) 479 (69.2) 57 (64.8) .93
WCC 6.50 x 109/L 244 (27.6) 269 (37.8) 39 (44.3) <.001
FEV1/FVC <0.7 137 (15.5) 155 (21.8) 28 (31.1) <.001
Visual impairment 183 (20.7) 226 (31.7) 41 (45.6) <.001
Hearing impairment 15 (1.7) 29 (4.1) 3 (3.3) .012
IADL disability 44 (5.0) 78 (11.0) 24 (26.7) <.001
ADL Disability 2 (0.2) 23 (3.2) 7 (7.8) <.001
Hospital admission(s) 40 (4.5) 42 (5.9) 9 (10.0) .033
ADL, activities of daily living; BMI, body mass index; COPD, chronic obstructive
pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital
capacity; GDS, Geriatric Depression Scale; IADL, instrumental ADL; MMSE, Mini-
Mental State Examination; WCC, white cell count.
Values are n (%).
Table 2
Final Model of Signiﬁcant Correlates of Prefrailty-Frailty From Binary Logistic
Regression Via Backward Stepwise Variable Selection in Development Cohort
(n ¼ 1685)
B OR 95% CI P Risk Score
Age 75 0.814 2.26 (1.62e3.15) .000 2
No formal education 0.323 1.38 (1.05e1.81) .020 1
Heart failure 0.467 1.59 (1.07e2.38) .022 1
Asthma/COPD 0.532 1.70 (1.02e2.84) .042 2
Stroke 0.760 2.14 (1.11e4.11) .023 2
Depression 1.090 2.97 (1.16e7.62) .023 3
Hearing impairment 0.848 2.34 (1.21e4.52) .012 3
Visual impairment 0.422 1.52 (1.19e1.95) .001 1
Low hemoglobin 0.341 1.41 (1.13e1.75) .002 1
Nutritional risk score 3 0.650 1.92 (1.52e2.42) .000 2
WBC (x 109/L) 6.5 0.421 1.52 (1.21e1.91) .000 1
FEV1/FVC <0.7 0.307 1.36 (1.04e1.78) .026 1
eGFR <60 (mL/min/1.73m2) 0.449 1.57 (1.01e2.43) .044 1
CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; eGFR, esti-
mated glomerular ﬁltration rate; FEV1, forced expiratory volume in 1 second; FVC,
forced vital capacity; WBC, white blood cells.
Signiﬁcant predictors were retained at P < .05 in the ﬁnal model.
Table 3
Clinical Frailty Risk Indicator (C-FRI) Proﬁle at Baseline, Validation Cohort (n¼ 2478)
Variables Risk Score n %
Whole sample 2478 100
Age 75 3 319 12.9
No formal education 2 468 18.8
Heart failure 1 87 3.5
Respiratory problems (asthma, COPD) 2 99 4.0
FEV1/FVC <0.7 1 644 26.0
eGFR<60 (ml/min/1.73m2) 2 1035 41.8
Stroke 4 92 3.7
Depressive symptoms 4 335 13.5
Hearing impairment 4 67 2.7
Visual impairment 2 837 33.8
Low hemoglobin 1 339 13.7
Nutritional risk score 3 3 1229 49.6
WBC (x 109/L) 6.5 2 715 28.9
Frailty Risk Index (summed scores)
0 268 10.8
1 357 14.4
2 412 16.6
3 361 14.6
4 281 11.3
5 246 9.9
6 184 7.4
7 145 5.9
8 96 3.9
9 50 2.0
10 30 1.2
11e14 48 1.9
CHS frailty status
Robust (0) 1290 52.1
Prefrail (1e2) 1105 44.6
Frail (3e5) 83 3.3
FRAIL status
Robust (0) 1878 75.8
Prefrail (1e2) 580 23.4
Frail (3e5) 20 0.8
CHS, Cardiovascular Health Study; COPD, chronic obstructive pulmonary disease;
eGFR, estimated glomerular ﬁltration rate; FEV1, forced expiratory volume in 1
second; FVC, forced vital capacity; WBC, white blood cells.
T.P. Ng et al. / JAMDA 15 (2014) 635e642638(Table 4). The ability of the FRI to predict frailty (CHS Frailty score 3)
is shown in the ROC curve (Figure 2), with area under the ROC of
0.890.
In longitudinal analyses, FRI scores at baseline were signiﬁcantly
associated with IADL-ADL dependency, hospitalization, lowest quin-
tile of SF12-PCS scores, and combined adverse health outcomes at
follow-up, controlling for age, gender, housing status, smoking,
multicomorbidity, and baseline IADL-ADL dependency status
(or hospitalization in past year, SF12-PCS as appropriate) (Table 5).
This was also observed in the sample that excluded participants who
had the adverse health outcomes at baseline. The area under the ROC
curve for FRI prediction of IADL-ADL dependency was 0.715, relatively
greater than the areas under the curve (AUCs) for the CHS Frailty scaleand a comparable FRAIL scale (Table 6; Figure 3). Similarly greater
AUC values for FRI versus CHS Frailty scale and FRAIL scale were
observed for hospitalization and SF12-PCS outcomes.
Discussion
The exploration of determinants of frailty are important for
identifying modiﬁable risk factors, proﬁling clinical risk indicators,
Fig. 1. (A) Prevalence of prefrail and frailty by Frailty Risk Index. (B) Estimated prob-
ability of frailty by Frailty Risk Index.
Fig. 2. Receiver operating curve: FRI prediction of frailty (CHS Frailty Index 3).
Table 5
Association of Frailty Risk Index With Adverse Health Outcomes at 2-Year Follow-
up: Validation Cohort, Whole Sample and Baseline AHO-Free Sample (Participants
Free of AHO at Baseline)
AHO Per Unit of Clinical Frailty Risk Score
Whole sample AHO-Free at Baseline
T.P. Ng et al. / JAMDA 15 (2014) 635e642 639and targeting population subgroups for early intervention among
people identiﬁed to be at risk of becoming frail. In this study, we
investigated 40 known and putative risk factors of frailty, more than
any prior studies. The Women’s Health Initiative Observational Study
(WHI-OS)38 examined as many as 23 variables, but did not investigate
cognitive, nutritional, or blood measurement variables. In this study,
all factors, with only 5 exceptions, were found to be associated with
frailty in bivariate analyses, consistent with those reported in the
WHI-OS. Other studies also have reported positive associations of
frailty with age, stroke, COPD/asthma, visual impairment, and an-
emia.2,18,19,39e41 Interestingly, both this study and the WHI-OS found
that cancer was not associated with frailty.
Depression in particular appeared to be an important contributor,
in agreement with other studies.16e18,42,43 On the other hand, theTable 4
Odds Ratio of Association of Frailty Risk IndexWith Prefrail and Frail Status: Baseline
Analysis, Validation Cohort (n ¼ 2478)
Frailty Risk Index Prefrail (CHS: 1e2) Frail (CHS: 3þ)
OR 95% CI P OR 95% CI P
Per unit score 1.23 (1.19e1.27) <.001 1.80 (1.65e1.95) <.001
0e3 1 1
4e6 1.9 (1.6e2.3) <.001 9.3 (3.9e21.9) <.001
7e9 2.6 (2.0e3.5) <.001 38.3 (16.4e89.4) <.001
10e12 14.0 (5.9e32.9) <.001 433.0 (133.9e1399.6) <.001
CHS, Cardiovascular Health Study; CI, conﬁdence interval.association of cognitive impairment with frailty, as reported in other
studies,12,44,45 was observed only in bivariate analyses, but failed to be
selected in the ﬁnal model, plausibly because it was substituted by
depression, stroke, and congestive heart failure, with which it also
shares common pathophysiologic factors, such as atherosclerosis and
chronic inﬂammation.46,47
Inadequate dietary intake and nutritional deﬁciencies are
considered important causes of age-related sarcopenia, dynapenia,
and frailty.48,49 Studies have shown that obesity, increased number of
micronutrient deﬁciencies and low serum beta-carotenoids were
signiﬁcant risk factors for frailty,13,22 although one study using a
detailed dietary questionnaire failed to demonstrate that low energy
intake was signiﬁcantly associated with frailty.49 Our study shows
that in place of these nutritional variables, a simple screening mea-
sure of poor nutritional risk was independently associated with
frailty.
Elevated levels of immune markers of chronic inﬂammation, such
as CRP and IL-6, have been shown to be associated with frailty. InOR (95% CI) P OR (95% CI) P
IADL-ADL dependency 1.19 (1.11e1.27) <.001 1.16 (1.06e1.26) <.001
Hospitalization 1.14 (1.05e1.24) .002 1.17 (1.07e1.28) <.001
Lowest quintile SF12-PCS 1.17 (1.11e1.25) <.001 1.22 (1.13e1.33) <.001
Combined Adverse Health
Outcomes
1.16 (1.09e1.22) <.001 1.20 (1.11e1.30) <.001
ADL, activities of daily living; AHO, adverse health outcome; CI, conﬁdence interval;
IADL, instrumental ADL; SF12-PCS, Short Form 12 Physical Component Summary.
Frailty Risk Index (FRI) was analyzed as a continuous variable in the regression
model.
Covariates in model: age, gender, housing status, smoking, multicomorbidity,
and baseline IADL-ADL dependency status (or hospitalization in past year/SF12-PCS/
SF12-MCS as appropriate).
Table 6
Receiver Operating Characteristic Analyses of FRI, CHS Frailty Scale, and FRAIL Scale Predicting IADL-ADL Dependency, Hospitalization, and Lowest Quintile SF12-PCS Quality of
Life, and Any AHO
IADL-ADL Dependency Hospitalization Lowest Quintile SF12-PCS Any AHO
AUC SE P AUC SE P AUC SE P AUC SE P
FRI Index 0.715 0.018 .0001 0.626 0.027 .0001 0.703 0.015 .0001 0.692 0.014 .0001
CHS Frailty Scale 0.682 0.019 .0001 0.559 0.027 .028 0.637 0.017 .0001 0.634 0.015 .0001
FRAIL Scale 0.624 0.020 .0001 0.598 0.028 .0001 0.618 0.018 .0001 0.613 0.016 .0001
ADL, activities of daily living; AHO, adverse health outcome; AUC, area under the curve; CHS, Cardiovascular Health Study; CI, conﬁdence interval; FRI, Frailty Risk Index; IADL,
instrumental ADL; SF12-PCS, Short Form 12 Physical Component Summary.
P indicates signiﬁcance test of null hypothesis: AUC ¼ 0.50.
T.P. Ng et al. / JAMDA 15 (2014) 635e642640turn, circulating IL-6 level is inversely associated with hemoglobin
concentration in frail older adults, and low hemoglobin has been
found to be independently associated with frailty. WCC is a well-
recognized cellular marker of systemic inﬂammation and found in 2
studies to be associated with greater risk for cardiovascular disease,
mortality, and frailty.15,20 Our study replicates the signiﬁcant inde-
pendent association of increased WCC with frailty. These results
hence support the use of hemoglobin and WCC as simple, inexpen-
sive, and routinely available clinical indicators of systemic inﬂam-
mation and age-associated immune system decline associated with
frailty.
The 13 independent predictors selected in the ﬁnal regression
model represent an essential set of salient clinical risk indicators of
prefrailty and frailty. It is noteworthy that these frailty risk factors are
reﬂective of multiple system involvements for frailty. They includeFig. 3. ROC analyses of Frailty Risk Scale, CHS Frailty Scale, and FRAIL scale predicting IADL-
and all adverse health outcomes (D).psychosocial, central nervous system (CNS) mood and sensory,
cardiovascular, respiratory, renal, nutritional, and immune elements,
in keeping with current understanding of the multicausation of
frailty. The weighted scores assigned to each risk factor suggest
stronger elements of CNS mood, sensory, and nutritional-immune
involvements. The combined weight was 9 of a total of 21 for CNS
mood and sensory involvement, and 4 of 21 for nutritional-immune
involvement.
The FRI scores predicted frailty in this elderly population well: a
greater number of risk factors and a higher risk score identiﬁed more
individuals with frailty, and predicted a greater risk of developing
functional dependency, hospitalization, and impaired quality of life.
Indeed in this population, the FRI was comparable to the CHS Frailty
scale and the FRAIL scale in predicting these adverse health out-
comes. All the instruments have the ability to categorize individualsADL dependency (A), hospitalization (B) and lowest quintile SF12-PCS quality of life (C),
T.P. Ng et al. / JAMDA 15 (2014) 635e642 641as prefrail or frail at one point in time; however, the FRI with its
continuous scores has the additional advantage of greater sensitivity
in assessing change in risks over time.
It is possible that inclusion of additional factors, such as measures
of lean muscle mass, inﬂammatory markers, or homocysteine levels
may further improve the predictive power of the frailty risk score.
These are generally not routinely available in primary care settings,
but they may make it more useful in hospital-based settings. Another
limitation is that the FRI has not been externally evaluated on mor-
tality and institutionalization, and these should be evaluated in future
studies. Comparison of frailty prevalence in this study with other
studies using the CHS criteria for frailty may be limited by modiﬁ-
cations to the operational deﬁnitions used; for example, to deﬁne
weakness, dominant knee extension instead of handgrip strength was
used in this study. However, these modiﬁcations do not affect the
construct and criterion validity of the FRI in this study. Finally, non-
Chinese ethnicity was associated with greater prevalence of frailty;
the prevalence of many frailty-related risk factors are known to be
greater among Malays and Indians, and it is possible that the risk
predictor components and weights for FRI score may not be the same
in different ethnic groups. The numbers and proportions with Malay
and Indian ethnicities in this study sample were too small to permit
stratiﬁed analysis by ethnic groups. However, we noted in the whole
sample analysis that ethnicity in the presence of other risk variables
was not selected as a signiﬁcant risk variable in the FRI.
The FRI may be used routinely in primary care settings as a simple
clinical risk indicator tool for frailty among elderly persons, and also
as a compound variable to adjust for risk factors in research. Existing
frailty scales such as the FI-CGA and the MPI-CGA are relatively
resource-intensive prognostic tools useful in hospital geriatric set-
tings for assessing mortality risks or need for nursing home care.
Other brief screening tools, such as FRAIL and GFS, may be useful for
identifying frail individuals in primary care, but the presence of frailty
risk factors need to be further assessed for intervention purposes. In
this context, the FRI is thus a useful rapid assessment tool to identify
vital body system deﬁcits underlying the frailty syndrome. The FRI
does not replace other briefer screening tools to identify individuals
with frailty, but is most useful as a secondary tool that classify
patients as prefrail or frail to target speciﬁc risks for monitoring or
intervention purposes.
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